Connect with us

Business

Devon family business wins appeal for food and education centre that could create 75 jobs

Published

on

Business Live

Plans were initially refused by the local council but a government inspector has overturned the decision

The current location of Goosemoor, near Dart's Farm (Image courtesy: Google Maps).

The current location of Goosemoor, near Dart’s Farm(Image: Google Maps)

A Devon business will be permitted to build an ‘educatering’ facility after successfully appealing a decision that initially rejected its proposals.

Advertisement

Goosemoor, which has been owned by the Pritchard family for nearly 70 years, sought permission to build a site in East Devon that would primarily house a food distribution centre for its school meals operation.

While this is expected to run round-the-clock for six days a week, the business also envisaged the development, in the parish of Woodbury, would have a classroom where pupils could discover the origins of their food and prepare meals, alongside open areas where crops would be cultivated to supply ingredients.

Local planning authorities declined to approve the scheme earlier this year, citing concerns about its effect on the surrounding countryside – the majority of which carries some form of protected status – and the view it would almost certainly require car access, which could itself prove troublesome for others using the narrow rural lane which lacks pavements or street lighting.

East Devon District Council’s planning committee also raised concerns about the possible impact on neighbouring properties, which include Grade II listed North Lodge, Nutwell Cottages and Nutwell Lodge Hotel.

Advertisement
A drawing of a possible layout of the proposed Goosemoor 'educatering' facility (Image courtesy: EDDC).

A drawing of a possible layout of the proposed Goosemoor ‘educatering’ facility (Image: Local Democracy Reporting Service / EDDC)

However, a government planning inspector has reversed the decision – though with 26 conditions attached to the approval. Goosemoor has welcomed the ruling, while a council spokesperson said it was “disappointed” given its “clear concerns” about the proposal.

Although inspector Laura Cuthbert acknowledged several of the issues raised by the council, she assigned most of them only ‘limited’ or ‘moderate’ weight, while affording “significant weight” to the potential employment benefits the scheme could deliver and its broader economic impact.

Within her report, the inspector indicated the development could generate as many as 75 new jobs.

Citing the council’s own economic development officer, Ms Cuthbert noted the authority had recently acknowledged a “critical and well-established shortage of available employment land” in East Devon, which was “constraining inward investment, local business growth and forcing some employers to leave the district”.

Advertisement

Ms Cuthbert said: “These comments indicate that concerns regarding the availability of employment land and commercial premises remain significant and ongoing.

“Consequently, notwithstanding the council’s emerging strategy to address this matter, there remains an acknowledged and substantial shortfall in employment land across the district.

“Whilst future allocations may assist in meeting that need, their delivery remains uncertain at present. Having regard to the evidence before me, I conclude that the proposal would make a meaningful contribution towards addressing the current shortage of employment land and premises.”

Jamie Walsh, the founder and director of Goosemoor Educatering, welcomed the decision.

Advertisement

“The appeal has gone our way, and I think the process was pretty considered,” he said.

“It was back and forth from both sides, but what was pleasing is that in the appeal format, we could answer any queries, statements or questions and so it felt a lot more like our voice was heard [than at the planning committee].

“The inspector kept mentioning the planning balance and it came down more in our favour with the potential negatives not being enough to block the application.”

Mr Walsh said he hoped construction on the site would get under way in spring next year, once the firm has met the planning conditions attached to the scheme.

Advertisement

A spokesperson for East Devon District Council said the authority was “disappointed” the appeal had been allowed.

“Our position was that the site conflicted with countryside protection policies, was in an unsustainable location with very limited access to public transport, walking and cycling routes, and would cause harm to the landscape and to the setting of nearby listed buildings,” the spokesperson said.

“While the inspector agreed with all of these concerns, they concluded that the economic benefits of the scheme outweighed the harm identified, in the absence of a suitable alternative site.

“We respect the inspector’s decision, but our position remains that development in the countryside must be carefully managed and located where it can be properly supported by sustainable transport and infrastructure.”

Advertisement
Continue Reading
Click to comment

You must be logged in to post a comment Login

Leave a Reply

Business

Boeing: Let's Not Get Carried Away

Published

on

Boeing: Let's Not Get Carried Away

Boeing: Let's Not Get Carried Away

Continue Reading

Business

Kiniksa Pharmaceuticals Shares Surge 21% on Strong ARCALYST Sales and Raised 2026 Guidance

Published

on

Microsoft buys Activision, in New York City

BOSTON — Shares of Kiniksa Pharmaceuticals International plc jumped more than 21% in morning trading Tuesday after the biopharmaceutical company reported second-quarter results that exceeded expectations and raised its full-year sales outlook for its flagship drug treating recurrent pericarditis.

Kiniksa stock rose $13.43, or 21.14%, to $76.97 as of 10:06 a.m. EDT on the Nasdaq. The move came after the company announced ARCALYST (rilonacept) net product revenue of $243.6 million for the quarter ended June 30, representing approximately 55% growth from the same period a year earlier. The figure surpassed analyst estimates.

The company also increased its expected 2026 ARCALYST net product revenue guidance to a range of $980 million to $995 million, up from the previous range of $930 million to $945 million. Kiniksa reported net income of $25.4 million for the quarter and ended the period with $525.9 million in cash, cash equivalents and short-term investments, and no debt.

In a statement accompanying the results, the company highlighted continued commercial momentum. Approximately 21% of the estimated 14,000 multiple-recurrence recurrent pericarditis patients in the United States were actively on ARCALYST therapy at the end of the second quarter. More than 5,000 prescribers have written prescriptions for the drug since its launch in the indication.

Advertisement

“In the second quarter, Kiniksa continued to drive growth in new and repeat prescribers of ARCALYST in recurrent pericarditis,” the company said in its earnings release. The results reflect expanding adoption of the only FDA-approved therapy specifically indicated for the condition, a painful and debilitating autoinflammatory cardiovascular disease characterized by inflammation of the pericardium.

Beyond the commercial performance, Kiniksa provided an update on its pipeline. An interval analysis from the Phase 2 dose-focusing portion of the KPL-387 Phase 2/3 trial in recurrent pericarditis showed rapid and sustained reductions in pain and inflammation at the 300 mg subcutaneous once-monthly dose selected for Phase 3. Time to treatment response was a median of 4.0 days, and time to C-reactive protein normalization was a median of 8.0 days. Efficacy was durable throughout the monthly dosing interval, and the drug was generally well-tolerated, consistent with the known safety profile of interleukin-1 pathway inhibition.

The company has initiated and is dosing patients in PASTORALE, the pivotal Phase 3 randomized withdrawal trial evaluating KPL-387 300 mg subcutaneous once-monthly in a liquid formulation. Kiniksa targets potential commercialization of KPL-387 in the 2028-2029 timeframe. It also remains on track to initiate a Phase 1 first-in-human trial for KPL-1161, an Fc-modified IL-1 antagonist designed for once-quarterly dosing, by the end of 2026.

Sanj K. Patel, Kiniksa’s chief executive officer, commented on the dual progress in commercialization and clinical development. “In our clinical portfolio, KPL-387 Phase 2 data supported initiation of the pivotal Phase 3 trial, PASTORALE, which is now enrolling and dosing patients. We are excited to advance KPL-387 with its target product profile of once-monthly subcutaneous dosing in a liquid formulation. We expect to bring this potential additional treatment option to patients in the 2028/2029 timeframe. Additionally, we continue to develop KPL-1161 with a target profile of once-quarterly dosing and are on track to initiate a Phase 1 trial by the end of this year.”

Advertisement

The strong quarterly performance builds on earlier 2026 momentum. In the first quarter, ARCALYST revenue had already shown robust growth, prompting a previous upward revision to guidance. The further increase announced Tuesday signals confidence that underlying demand remains solid and that market penetration has room to expand. Recurrent pericarditis affects an estimated larger patient population beyond the multiple-recurrence segment currently being captured, and earlier treatment approaches could further broaden the addressable market over time.

Kiniksa focuses on developing and commercializing therapies for diseases with unmet need, with particular emphasis on cardiovascular indications. ARCALYST, an interleukin-1 alpha and beta cytokine trap, received FDA approval for recurrent pericarditis and has become the cornerstone of the company’s revenue. The pipeline assets KPL-387 and KPL-1161 aim to offer differentiated dosing convenience while targeting the same validated IL-1 pathway.

Analysts had anticipated solid results given the trajectory of ARCALYST prescriptions and the limited competition in the recurrent pericarditis space. The combination of a clear revenue beat, a meaningful guidance raise, positive mid-stage data and Phase 3 initiation provided multiple catalysts that investors rewarded with a sharp revaluation of the shares. The stock had already risen substantially year-to-date prior to the report, reflecting growing recognition of the commercial potential of ARCALYST and the strategic value of the IL-1 franchise.

The company expects its current operating plan to remain cash-flow positive on an annual basis. With a strengthened balance sheet and no debt, Kiniksa is positioned to fund ongoing commercial efforts and clinical development without near-term financing needs. Management is scheduled to discuss the results further on a conference call and webcast.

Advertisement

Investors will continue to monitor prescription trends, the pace of new prescriber adoption and any updates from the PASTORALE trial. Success with KPL-387 could eventually provide a next-generation option with less frequent dosing than ARCALYST’s weekly regimen, potentially expanding the franchise. For now, the second-quarter numbers and raised outlook underscore that the existing product continues to gain traction in a market that remains underpenetrated.

The rapid share-price reaction underscores the market’s sensitivity to execution in rare-disease commercialization and clear clinical progress. Kiniksa’s results arrive amid a broader biotech environment in which companies demonstrating both commercial traction and pipeline advancement have often been rewarded. The day’s gains place the stock near the upper end of its 52-week range as the company advances its dual commercial and development strategy in cardiovascular inflammation.

Continue Reading

Business

Rescuers in Japan haul survivors from collapsed mall as earthquake toll rises to 13

Published

on


Rescuers in Japan haul survivors from collapsed mall as earthquake toll rises to 13

Continue Reading

Business

Liontown Limited (LINRF) Q4 2026 Earnings Call Transcript

Published

on

OneWater Marine Inc. (ONEW) Q1 2026 Earnings Call Transcript